$18.18
2.71% today
Nasdaq, Apr 02, 09:16 pm CET
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

CareDx, Inc. Stock price

$17.70
-3.43 16.23% 1M
-13.23 42.76% 6M
-3.71 17.33% YTD
+7.38 71.51% 1Y
-21.28 54.59% 3Y
-1.76 9.04% 5Y
+12.14 218.35% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.05 0.28%
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

Key metrics

Market capitalization $981.04m
Enterprise Value $748.76m
P/E (TTM) P/E ratio 17.40
EV/FCF (TTM) EV/FCF 23.73
EV/Sales (TTM) EV/Sales 2.24
P/S ratio (TTM) P/S ratio 2.94
P/B ratio (TTM) P/B ratio 2.56
Revenue growth (TTM) Revenue growth 19.07%
Revenue (TTM) Revenue $333.79m
EBIT (operating result TTM) EBIT $-42.18m
Free Cash Flow (TTM) Free Cash Flow $31.56m
Cash position $260.65m
EPS (TTM) EPS $1.02
P/E forward negative
P/S forward 2.65
EV/Sales forward 2.02
Short interest 13.52%
Show more

Is CareDx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

CareDx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

5x Buy
56%
4x Hold
44%

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

Buy
56%
Hold
44%

Financial data from CareDx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
334 334
19% 19%
100%
- Direct Costs 112 112
7% 7%
34%
222 222
26% 26%
66%
- Selling and Administrative Expenses 172 172
4% 4%
52%
- Research and Development Expense 72 72
12% 12%
22%
-23 -23
73% 73%
-7%
- Depreciation and Amortization 19 19
8% 8%
6%
EBIT (Operating Income) EBIT -42 -42
59% 59%
-13%
Net Profit 62 62
133% 133%
19%

In millions USD.

Don't miss a Thing! We will send you all news about CareDx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CareDx, Inc. Stock News

Neutral
Business Wire
5 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA). CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October 28, 2021, t...
Neutral
Business Wire
13 days ago
TORONTO--(BUSINESS WIRE)---- $CDNA #CIFinancial--CI Global Asset Management has received securityholder approval to proceed with the merger of six mutual funds and two ETFs into other mandates.
Neutral
PRNewsWire
19 days ago
NEW YORK and NEW ORLEANS , March 14, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
More CareDx, Inc. News

Company Profile

CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Head office United States
CEO John Hanna
Employees 650
Founded 1998
Website www.caredx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today